<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805736</url>
  </required_header>
  <id_info>
    <org_study_id>MA-BC-Ⅱ-021</org_study_id>
    <nct_id>NCT04805736</nct_id>
  </id_info>
  <brief_title>Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer</brief_title>
  <official_title>A Pilot Study of Single-Dose Camrelizumab and/or Microwave Ablation in Women With Early-Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ablative therapy, as a local treatment modality for tumors, has an immune activating effect.&#xD;
      To explore the synergistic effect of microwave ablation combined with PD-1 inhibitors, this&#xD;
      prospective, open-label, multi-cohort, single-center clinical study was conducted. To compare&#xD;
      the feasibility and safety of preoperative microwave ablation alone, with or without&#xD;
      camrelizumab in patients with early newly diagnosed breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Microwave Ablation Combined With Camrelizumab</measure>
    <time_frame>3 months</time_frame>
    <description>Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete ablation rate</measure>
    <time_frame>1 day</time_frame>
    <description>The proportion of patients with complete ablation was calculated for all patients. Complete ablation was defined as: tissue section at the ablation margin that was negative by histochemical staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of ultrasound</measure>
    <time_frame>1 day</time_frame>
    <description>Preoperative ultrasonography was performed. The negative predictive value of ultrasound was calculated by comparing the pathology report. Negative predictive value = number of patients with negative pathology and negative ultrasound/number of patients with negative ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Immunogenicity</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of subjects with immune response to synergistic therapy detected by biomarkers in peripheral blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast self evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>Breast self evaluation for patients will be assessed by Functional Assessment of Cancer Therapy - Breast (FACT-B) scale scores.The FACT-B consists of 44 self-report items and assesses the specific breast cancer-related quality of life on 4 general and 1 breast-cancer specific subscale. A higher score indicates a higher cancer-related quality of life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Microwave Ablation alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microwave Ablation+ Breast Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Camrelizumab alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab+ Breast Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microwave Ablation &amp; Camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microwave Ablation + Camrelizumab + Breast Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microwave Ablation</intervention_name>
    <description>Image-guided microwave ablation 7-10 days prior to surgery</description>
    <arm_group_label>Microwave Ablation &amp; Camrelizumab</arm_group_label>
    <arm_group_label>Microwave Ablation alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab 200 mg was given a few days after microwave ablation</description>
    <arm_group_label>Camrelizumab alone</arm_group_label>
    <arm_group_label>Microwave Ablation &amp; Camrelizumab</arm_group_label>
    <other_name>SHR-1210</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast Surgery</intervention_name>
    <description>Standard of care breast conserving surgery or radical mastectmoy</description>
    <arm_group_label>Camrelizumab alone</arm_group_label>
    <arm_group_label>Microwave Ablation &amp; Camrelizumab</arm_group_label>
    <arm_group_label>Microwave Ablation alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female.&#xD;
&#xD;
          2. Age 20-65 years.&#xD;
&#xD;
          3. Invasive carcinoma confirmed by core biopsy.&#xD;
&#xD;
          4. Newly diagnosed breast cancer patients, without adjuvant therapy.&#xD;
&#xD;
          5. Imaging findings showed a single breast tumor with a maximum diameter of 3 cm, no&#xD;
             distant metastasis, and no invasion of the skin and chest wall.&#xD;
&#xD;
          6. Systematic ultrasound is able to visualize lesions.&#xD;
&#xD;
          7. Surgical treatment was planned.&#xD;
&#xD;
          8. The functional level of major organs must meet the following requirements:&#xD;
&#xD;
               1. blood routine: neutrophil (ANC) ≥ 1.5 × 109/L; platelet count (PLT) ≥ 90 × 109/L;&#xD;
                  hemoglobin (Hb) ≥ 90 g/L;&#xD;
&#xD;
               2. blood biochemistry: total bilirubin (TBIL) ≤ upper limit of normal (ULN); alanine&#xD;
                  aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN; alkaline&#xD;
                  phosphatase ≤ 2.5 × ULN; blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 ×&#xD;
                  ULN;&#xD;
&#xD;
               3. coagulation: international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5&#xD;
                  × ULN; activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.&#xD;
&#xD;
               4. Heart: left ventricular ejection fraction (LVEF) ≥ 50% as assessed by&#xD;
                  echocardiography (ECHO) or multigated acquisition (MUGA).&#xD;
&#xD;
               5. Thyroid function: thyroid stimulating hormone (TSH) ≤ ULN; if abnormal, T3 and T4&#xD;
                  levels should be investigated, and normal T3 and T4 levels can be included.&#xD;
&#xD;
               6. Urinalysis: urine protein &lt; 2 +, if urine protein ≥ 2 +, 24-hour urine protein&#xD;
                  quantification must show protein ≤ 1 g.&#xD;
&#xD;
          9. Voluntarily participate in this study, sign informed consent, have good compliance and&#xD;
             are willing to cooperate with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Tumor involving skin, ulceration, inflammatory breast cancer patients&#xD;
&#xD;
          2. Fatty breast cancer.&#xD;
&#xD;
          3. Tumors on the deep surface of areolar region&#xD;
&#xD;
          4. KPS score &lt; 70, or ECOG score &gt; 2&#xD;
&#xD;
          5. Patients with a history of concomitant collagen connective tissue disease, or any&#xD;
             active autoimmune disease or autoimmune disease.&#xD;
&#xD;
          6. Prior radiotherapy or prior use of investigational drugs or other immunosuppressive&#xD;
             agents&#xD;
&#xD;
          7. Heart, brain, lung, kidney and other vital organ failure, liver and kidney&#xD;
             dysfunction;&#xD;
&#xD;
          8. Uncorrectable severe coagulopathy&#xD;
&#xD;
          9. Patient is pregnant or lactating&#xD;
&#xD;
         10. Poor glycemic control in diabetes&#xD;
&#xD;
         11. Patients with foreign body implantation around the tumor&#xD;
&#xD;
         12. Patients with severe scars on the skin of the treatment area (protruding from the skin&#xD;
             surface, width ≥ 1 cm)&#xD;
&#xD;
         13. History of chronic immunosuppression, prior immunotherapy, recent vaccination (&lt; 4&#xD;
             weeks)&#xD;
&#xD;
         14. Human immunodeficiency virus (HIV) infection, active hepatitis B (hepatitis B&#xD;
             indicates antigen positive and HBV DNA ≥ 500 IU/ml), hepatitis C (hepatitis C antibody&#xD;
             positive and HCV-RNA above the lower limit of detection of the analytical method).&#xD;
&#xD;
         15. Concurrent medical conditions that, in the judgment of the investigator, would&#xD;
             jeopardize the subject's safety, could confound the study results, or affect the&#xD;
             subject's completion of this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenbin Zhou, Professor</last_name>
    <phone>025-68308162</phone>
    <email>zhouwenbin@njmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenbin Zhou, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>April 18, 2021</last_update_submitted>
  <last_update_submitted_qc>April 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Shui Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Ablation</keyword>
  <keyword>PD-1</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

